This article is more than 5 years old. Information may no longer be current.

Alimera reports third-quarter net loss of $6.5 million

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ATLANTA — Marketing expenses for Alimera increased more than 60% in the third quarter of 2011 compared with the same period in 2010 as the company worked to develop awareness and launch plans for Iluvien, according to a press release.

Overall, the company reported $6.5 million, or 21 cents per share, in losses compared with $6.1 million, or 20 cents per share, in the third quarter of 2010, the release said.

A study examining physician utilization of Iluvien (fluocinolone acetonide intravitreal insert) has been initiated in response to a request by the U.S. Food and Drug Administration. The company aims to enroll 100 eyes in the study before launching the intravitreal insert commercially; 54 eyes have been enrolled so far.

"We remain confident that Iluvien has the potential to be a very useful treatment to address [diabetic macular edema], a blinding disease with limited pharmacological options," Dan Myers, Alimera's president and chief executive officer, said in the release.